Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 May 27;14(9):3439–3469. doi: 10.7150/thno.93962

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The author(s)

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

PMC Copyright notice

Individualized treatment prediction and biological validation of MPS-based individualized treatment in the established human NB cells models. (A) Heatmap exhibited kPMGs expression (these were used for MPS risk-stratification), MPS score and MPS group of each included neuroblastoma CCLs; also shown are the identified therapeutic agents and their AUCs. (B) Difference of each identified drug's AUC between MPS-subtyped neuroblastoma. (C) IC50 differences of AZD7762 and etoposide between MPS-identified NB subgroups. (D) and (E), Results of EdU assays, the scale bar is 50μm. (F) and (H), transwell assays measured the invasion capacity of NB cells after treatment. (G) and (I), measurement of cell colonies formation capacity of NB cells after treatment.